Effect of Mirabegron on detrusor function in patients with Parkinson's disease complicated with overactive bladder
Objective To investigate the effect of Mirabegron on detrusor function in patients with Parkinson's disease complicated with overactive bladder.Methods From May 2019 to November 2021,40 patients with Parkinson's disease complicated with bladder overactivity were enrolled and treated with Mirabegron orally for 12 weeks.Patients were divided into male group(23 cases)and fe-male group(17 cases)according to gender.Urodynamic examination,OABSS score and incontinence quality of life(I-QOL)scores were performed before and after treatment.Results Residual urine vol-ume(PVR)after treatment was less than 10 mL in all patients.The maximum bladder volume(MCC),initial urine volume(FDV)and bladder compliance(BC)after treatment were significantly higher than those before treatment,and the differences were statistically significant(all P＜0.05).Af-ter treatment,the number of uninhibited detrusor contraction(UDC)decreased significantly compared with that before treatment,with statistical significance(P＜0.05),and 9 cases of uninhibited detrusor contraction disappeared completely.There was no significant difference between the maximum urine flow rate(Qmax)before and after treatment and the detrusor pressure(PdetQmax)during the maximum urine flow rate(all P＞0.05).After treatment,the daily urine frequency,night urine frequency,ur-gent urination frequency,urinary incontinence frequency and OABSS were lower than those before treatment,and the differences were statistically significant(all P＜0.05).After 12 weeks of treat-ment,the I-QOL of patients was higher than that before treatment,and the difference was statistically significant(P＜0.05).Hypertension occurred in 1 patient,and no other adverse reactions occurred in all patients.Conclusions Mirabegron can significantly reduce the number of uninhibited contractions of detrusor muscle,improve bladder compliance,increase bladder volume,improve OAB symptoms,improve quality of life,and do not reduce detrusor pressure or increase the risk of urinary retention in patients with Parkinson's disease complicated with overactive bladder.
万方数据
维普
